AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

• Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

  Business - MarketWatch - 2 days ago
• 

  AbbVie shares tumble after schizophrenia drug disappoints

  Business - Financial Times - 2 days ago
• 

  Google’s AI-Fueled Results Bode Well for Rivals Amazon and Microsoft

  Business - Inc. - October 30

• Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

  Business - CNBC - October 31

• Bristol Myers’s stock pops as earnings top estimates and company raises guidance

  Business - MarketWatch - October 31
• 

  A promising schizophrenia drug showed mixed results. What does that mean for patients?

  Health - ABC News - October 31
• 

  MLB predictions, picks, best bets: Why pitching matchup bodes well for Aaron Judge, ride with Dodgers' offense

  Sports - CBS Sports - October 18

• Belarus arrests well-known analyst as crackdown on opposition continues

  World - ABC News - October 22
• 

  Officer apologises for calling Novichok victim 'well-known drug addict'

  Top stories - BBC News - November 4

More from MarketWatch

• ‘I handle my dad’s finances’: My father is in a nursing home and will get $100K in compensation. What should I do with it?

  Business - MarketWatch - 11 minutes ago

• Gaetz as Trump’s AG seen as bullish for pot stocks, but confirmation looks unlikely

  Business - MarketWatch - 16 minutes ago

• Disney’s stock surges as streaming profits grow and film releases shine

  Business - MarketWatch - 38 minutes ago

• ‘DJT’ stock flattens out as investors take in Trump’s cabinet moves

  Business - MarketWatch - 39 minutes ago

• 10-, 30-year Treasury yields fall from 4-month highs ahead of Powell appearance

  Business - MarketWatch - 57 minutes ago